Cancer News and Research

Latest Cancer News and Research

Patients with bone cancer can benefit from radical surgery

During a radical surgery to treat a rare bone cancer, surgeons at UC San Diego Health System and Moores Cancer Center removed 50 percent of a patient's pelvis. Instead of amputating the connected leg, the surgical team, comprised of orthopaedic, vascular and urologic experts, saved the entire limb. The patient was able to walk with assistance five weeks after surgery.

22 Mar 2011

Polypill may serve as viable option for developing countries to treat CVD risk prevention

For a patient at high risk of cardiovascular disease, keeping up with what pills to take at different times of the day can be tedious. Window sills lined with prescription bottles - a pill for cholesterol, another for blood pressure, and an aspirin to keep blood thin and flowing - the list can get quite long and, as a result, many people, especially the elderly, often forget doses or take the wrong pill at the wrong time.

22 Mar 2011

FDA accepts Arisaph's ARI-3037MO IND for phase I human clinical trial

Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.

22 Mar 2011

BDSI's BEMA drug delivery technology receives Canada patent

BioDelivery Sciences International, Inc. announced the issuance of a patent extending the exclusivity of the BioErodible MucoAdhesive drug delivery technology in Canada from 2017 to 2027. The patent was been reviewed by the Office of Patented Medicines for listing in the Canadian Patent Register and was found eligible for listing.

22 Mar 2011

Research shows being obese for longer period may increase risk of mortality

Monash University researchers have found the number of years individuals live with obesity is directly associated with the risk of mortality.

22 Mar 2011

City Of Hope opens new center for diabetes research and care

City of Hope has established a new Diabetes Research Center that will expand its pioneering investigations into diabetes, endocrinology and metabolic diseases, create an infrastructure to support translational research and enhance clinical care for diabetes and its related complications.

22 Mar 2011

USPTO grants patent to HistoRx methods for digital microscopy standardization

HistoRx, Inc., announced today that the U.S. Patent and Trademark Office has granted a patent protecting the company's methods for standardization of digital microscopy instruments in order to go beyond imaging to generating high-quality reproducible data that precisely relates to biomarker concentrations in tissue sections.

22 Mar 2011

Cephalon to acquire Gemin X Pharmaceuticals

Cephalon, Inc. announced today that it has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis. Gemin X stockholders could also receive up to $300 million in cash payments upon the achievement of certain regulatory and sales milestones.

22 Mar 2011

Bowel cancer incidence set to rise: Research

According to the latest research from the Cancer Council, the incidence of bowel cancer in Australia is set to rise to 21,000 cases a year in the next decade. The report shows that one in five cases are diagnosed at an advanced stage, due to a lack of screening. This research is being used to renew the Federal Government’s full funding and implementation of the national bowel cancer screening program. Funding for the program is due to expire at the end of June.

21 Mar 2011

Philanthropists triple-match public's donations for TGen's unTEAL cure ovarian cancer event

Philanthropists Foster and Lynn Friess will triple-match the public's donations - up to a total of $100,000 - for TGen's 2nd annual unTEAL a cure ovarian cancer event.

21 Mar 2011

Differences between therapeutic radiation therapy and exposure to excessive nuclear plant fallout radiation

"The Canadian Association of Radiation Oncology (http://www.caro-acro.ca) is the voice for specialists in Canada who treat patients' cancer with radiation. In that capacity," explains Dr. Matthew Parliament, president of CARO-ACRO, "we work with proven, controlled, targeted application of various forms of radiation therapy to treat and cure cancer."

21 Mar 2011

NIH spending at risk in budget battle

When House Republicans took power in 1995 determined to cut spending in a battle that shut down the U.S. government, then-House Speaker Newt Gingrich was persuaded to spare the National Institutes of Health.

21 Mar 2011

Abbott receives CE-Mark for new qualitative PCR-based HIV-1 test

Abbott (NYSE: ABT) announced today that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from dried blood spot and plasma specimens. The new assay is a long-awaited diagnostic tool for health officials in African nations and other resource-limited areas to detect HIV-1 infected infants at early stages and begin treatment when success is more likely.

21 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer.

21 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.

21 Mar 2011

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

A team of scientists from Princess Margaret Hospital have created an organic nanoparticle that is completely non-toxic, biodegradable and nimble in the way it uses light and heat to treat cancer and deliver drugs.

21 Mar 2011

Elevations in 5 amino acids may signal future disease risk

Measuring the levels of small molecules in the blood may be able to identify individuals at elevated risk of developing type 2 diabetes as much as a decade before symptoms of the disorder appear.

21 Mar 2011

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced a positive outcome from a pivotal Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

21 Mar 2011

Cancer News and Research

Latest Cancer News and Research

Patients with bone cancer can benefit from radical surgery

Polypill may serve as viable option for developing countries to treat CVD risk prevention

FDA accepts Arisaph's ARI-3037MO IND for phase I human clinical trial

BDSI's BEMA drug delivery technology receives Canada patent

Research shows being obese for longer period may increase risk of mortality

City Of Hope opens new center for diabetes research and care

USPTO grants patent to HistoRx methods for digital microscopy standardization

Cephalon to acquire Gemin X Pharmaceuticals

Bowel cancer incidence set to rise: Research

Philanthropists triple-match public's donations for TGen's unTEAL cure ovarian cancer event

Differences between therapeutic radiation therapy and exposure to excessive nuclear plant fallout radiation

NIH spending at risk in budget battle

Abbott receives CE-Mark for new qualitative PCR-based HIV-1 test

Sarsia Seed provides follow-up funding for APIM Therapeutics

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

Elevations in 5 amino acids may signal future disease risk

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in